secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-09-08T21:16:50+00:00
Accession:  0001193125-26-385362
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates 212Pb pipeline presentation; highlights NET/melanoma/FAP data targeting $45B market
--------------------------------------------------------------------------------

- Perspective Therapeutics updates corporate presentation for 212Pb radiopharma pipeline targeting a combined $45B+ solid tumor market.
- VMT-α-NET (SSTR2+ NETs): Phase 1/2a ASCO 2026 data shows durable disease control across all doses; safety profile from n=68 treated patients.
- VMT01 (melanoma/MC1R): preliminary anti-tumor activity at 3.0 mCi in Phase 1/2a; synergy with immune checkpoint inhibitors highlighted.
- PSV359 (FAP-ɑ) shows improved tumor retention in Phase 1/2a solid tumors; CCK2R81 in medullary thyroid cancer; data expected across programs in 2026.
- Platform supports direct-to-hospital delivery with regional 212Pb manufacturing and IP portfolio covering radiopharmaceutical value chain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526385362/0001193125-26-385362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526385362/catx-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-385362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer